ScholarIQanswers from OpenAlex & ORCID
Olivier Bouché
ResearcherPublications, citations & collaboration network
Olivier Bouché is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Olivier Bouché have?
ScholarIQindexed works
Olivier Bouché has 760 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Olivier Bouché have?
ScholarIQcitation count
Olivier Bouché has 43,313 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Olivier Bouché?
ScholarIQh-index
Olivier Bouché has an h-index of 84 in OpenAlex.
What is the i10-index of Olivier Bouché?
ScholarIQi10-index
Olivier Bouché has an i10-index of 300 in OpenAlex.
What is the ORCID of Olivier Bouché?
ScholarIQorcid
The ORCID for Olivier Bouché is on the source record.
What is the OpenAlex record for Olivier Bouché?
ScholarIQopenalex
The OpenAlex for Olivier Bouché is on the source record.
What are the most-cited papers on Olivier Bouché?
ScholarIQmost cited works
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade, I. Martel-Laffay, Christophe Hennequin, Pierre-Luc Etienne, V. Vendrely, Éric François, Guy de La Roche, Olivier Bouché, X. Mirabel, Bernard Denis, Laurent Mineur, Jean-François Berdah, M.-A. Mahé, Y. Bécouarn, Olivier Dupuis, Gérard Lledo, C. Montoto-Grillot, Thierry Conroy
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade, Isabelle Martel‐Lafay, Christophe Hennequin, Pierre-Luc Etienne, V. Vendrely, Éric François, Guy de La Roche, Olivier Bouché, X. Mirabel, Bernard Denis, Laurent Mineur, Jean-François Berdah, Marc-André Mahé, Y. Bécouarn, Olivier Dupuis, Gérard Lledo, Jean‐François Seitz, Laurent Bedenne, Béata Juzyna, Thierry Conroy
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial
Thierry André, Déwi Vernerey, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Roger Faroux, Serge Fratté, Marine Hug de Larauze, Sophie Paget‐Bailly, Benoist Chibaudel, Jérémie Bez, Jérôme Dauba, Christophe Louvet, Céline Lepère, Olivier Dupuis, Y. Bécouarn, May Mabro, Joëlle Egreteau, Olivier Bouché, G. Deplanque, Marc Ychou, Marie Pierre Galais, François Ghiringhelli, Louis Marie Dourthe, Jean‐Baptiste Bachet, Ahmed Khalil, Franck Bonnetain, Aimery de Gramont, Julien Taı̈eb, for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER
Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms
Louis de Mestier, Jérôme Cros, Cindy Neuzillet, Olivia Hentic, Axel Egal, Nelly Müller, Olivier Bouché, Guillaume Cadiot, Philippe Ruszniewski, Anne Couvelard, Pascal Hammel